Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.Novo Nordisk (NVO +3.51%), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty more pipeline candidates in the works.However, this area is attracting many more challengers looking to capitalize on its fast expansion. One of them is Viking Therapeutics (VKTX +2.34%), a mid-cap biotech. This smaller ...